Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Intravenous immune globulin G

Phase 1Small molecule

RRutgers, The State University of New Jersey

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

CIDPRecruiting

CIDPPhase 1

Recruiting

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

CIDP

NCT05584631

Clinical

Trials by Indication[1]

CIDP1 trial

IVIG vs SCIG in CIDP

Recruiting·RRutgers, The State University of New Jersey·Phase 1·NCT05584631·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intravenous immune globulin G. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intravenous immune globulin G compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intravenous immune globulin G. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rutgers, The State University of New Jersey company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: RRutgers, The State University of New Jersey

Related News